Skip to content

Intra-Cellular Therapies, Inc.: filings

Every Intra-Cellular Therapies, Inc. annual and quarterly report in the SEC record with the published financial measures it tagged, 48 filings, each linked to its SEC index.

Filings with published measures

Each page shows what one filing reported, as tagged in that filing, with the periods it covered. Later filings can restate a value; the company overview shows the latest-filed value per period.

FormFiledFiscal periodMeasuresFactsSEC accession
10-K2025-02-21fiscal FY 2024441670001628280-25-006993
10-Q2024-10-30fiscal Q3 2024421250001628280-24-044196
10-Q2024-08-07fiscal Q2 2024421210001628280-24-035386
10-Q2024-05-07fiscal Q1 202440840001628280-24-020849
10-K2024-02-22fiscal FY 2023441660001628280-24-006156
10-Q2023-11-02fiscal Q3 2023421220001628280-23-036217
10-Q2023-08-03fiscal Q2 2023421180001628280-23-027013
10-Q2023-05-04fiscal Q1 202342880001628280-23-015458
10-K2023-03-01fiscal FY 2022471680001193125-23-055176
10-Q2022-11-03fiscal Q3 2022411150001193125-22-276406
10-Q2022-08-09fiscal Q2 2022411150001193125-22-215635
10-Q2022-05-10fiscal Q1 202237790001193125-22-145709
10-K2022-03-01fiscal FY 2021431370001193125-22-059849
10-Q2021-11-09fiscal Q3 2021401080001193125-21-323812
10-Q2021-08-09fiscal Q2 2021401080001193125-21-239867
10-Q2021-05-10fiscal Q1 202140840001193125-21-155623
10-K2021-02-25fiscal FY 2020431250001193125-21-055751
10-Q2020-11-09fiscal Q3 202040990001193125-20-288507
10-Q2020-08-10fiscal Q2 2020401000001193125-20-214163
10-Q2020-05-07fiscal Q1 202040770001193125-20-135603
10-K2020-03-02fiscal FY 2019391040001193125-20-057888
10-Q2019-11-05fiscal Q3 201934880001193125-19-284125
10-Q2019-08-07fiscal Q2 201934900001193125-19-215347
10-Q2019-05-08fiscal Q1 201933680001193125-19-141425
10-K2019-02-27fiscal FY 2018391080001193125-19-054119
10-Q2018-11-07fiscal Q3 201834870001193125-18-320973
10-Q2018-08-02fiscal Q2 201834870001193125-18-236597
10-Q2018-05-03fiscal Q1 201829590001193125-18-150798
10-K2018-03-01fiscal FY 2017341010001193125-18-067144
10-Q2017-11-08fiscal Q3 201731840001193125-17-337324
10-Q2017-08-09fiscal Q2 201730790001193125-17-252755
10-Q2017-05-10fiscal Q1 201730600001193125-17-165965
10-K2017-03-01fiscal FY 2016341020001193125-17-065749
10-Q2016-11-09fiscal Q3 201632820001193125-16-764370
10-Q2016-08-04fiscal Q2 201629750001193125-16-671883
10-Q2016-04-28fiscal Q1 201629580001193125-16-563851
10-K2016-02-25fiscal FY 201532980001193125-16-478475
10-Q2015-11-05fiscal Q3 201529710001193125-15-368374
10-Q2015-08-05fiscal Q2 201529740001193125-15-278745
10-Q2015-04-30fiscal Q1 201529590001193125-15-162498
10-K2015-03-12fiscal FY 201432960001193125-15-089426
10-Q2014-11-03fiscal Q3 201429750001193125-14-394322
10-Q2014-08-12fiscal Q2 201429750001193125-14-306672
10-Q2014-05-05fiscal Q1 201427550001193125-14-182535
10-K2014-03-25fiscal FY 201329600001193125-14-114613
10-Q2013-11-05fiscal Q3 201333820001193125-13-427801
10-Q2013-08-15fiscal Q1 201316320001213900-13-004409
10-K2013-07-16fiscal FY 201214140001213900-13-003641

Inspect the source

Entity
Intra-Cellular Therapies, Inc. / CIK 0001567514
Captured
2026-09-21T17:20:04.465Z
SEC response SHA-256
d515a2828c30b442b80d2f88dbecd3b8d47803a78a686cc6f7c16f5ab9f2019e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001567514.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))